Option chain shows key data for Astellas Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Astellas Pharma.

Astellas Pharma (OTC:ALPMF) Stock, Option Chain

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

biotech shutter

Health Care

Initiation

Analyst Ratings

ALPMF

ALPMY

ELEV

Elevation Oncology&#39;s ADCs target CLDN18.2 and HER3, with EO-3021 showing promising Phase 1 results and a $6.6 billion TAM in gastric and pancreatic cancers.

Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise

SGMO

Biotech

Large Cap

News

Contracts

Movers

Trading Ideas

General

RHHBY

Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed positive Phase 3 results.

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

APLS

Analyst Color

Price Target

William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales estimates of $700 million by 2031 for Empaveli and $2 billion for Syfovre by 2030.

Syfovre&#39;s Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch

ASTELLAS PHARMA INC by Astellas Pharma, Inc.

Astellas Pharma Inc

Astellas Pharma

Comments

Astellas Pharma

Astellas Pharma (ALPMF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga